Intelligent Bio Solutions Achieves Record Monthly Sales of 12,500+ Units of Higher-Margin Cartridges in July

Rhea-AI Summary

Intelligent Bio Solutions (Nasdaq: INBS) reported record-breaking monthly cartridge sales in July 2025, shipping 519 boxes containing over 12,500 cartridges, marking a 60% year-over-year increase. The company's fingerprint sweat-based drug testing system operates on a razor/razor blade business model, where cartridges serve as high-margin consumables.

INBS secured a significant multi-site contract in the transportation sector and is experiencing growing demand for its drug testing solutions. The company plans to expand beyond Forensic Use Only settings in the U.S. market during the second half of 2025, while focusing on leveraging its installed base to drive recurring cartridge sales.

Positive

• Record monthly sales of 12,500+ cartridges, representing 60% year-over-year growth
• Secured new multi-site, high-volume contract in transportation sector
• Higher-margin consumables driving recurring revenue stream
• Growing pipeline of significant opportunities with increasing bids and tenders

Negative

• U.S. market expansion limited to Forensic Use Only settings until second half of 2025

News Market Reaction

-2.67%

1 alert

-2.67% News Effect

-$360K Valuation Impact

$13M Market Cap

0.6x Rel. Volume

On the day this news was published, INBS declined 2.67%, reflecting a moderate negative market reaction. This price movement removed approximately $360K from the company's valuation, bringing the market cap to $13M at that time.

Data tracked by StockTitan Argus on the day of publication.

Company reports all-time-high monthly cartridge sales for July with 60% year-on-year growth

NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its highest-ever monthly cartridge sales for July 2025, with a record 519 boxes shipped, representing over 12,500 cartridges and a 60% increase year-on-year.

Cartridges, a higher-margin consumable in the Company’s fingerprint sweat-based drug testing system, form the foundation of INBS’s razor/razor blade business model. This recurring revenue stream continues to grow as the Company secures new large contracts and further expands its global installed base. A recent significant tender win has secured a multi-site, high-volume contract in the transportation sector, and the continued expansion of the installed base has directly increased ongoing demand for consumables. The Company is seeing a growing pipeline of significant opportunities, with an increasing number of bids and tenders for large-scale deployments.

"July's record cartridge sales show the strength of our razor/razor blade business model and the momentum generated by major contract wins," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "As we expand our installed base and win larger opportunities, we see continued growth in cartridge demand, delivering attractive margins and a reliable revenue stream."

INBS remains focused on leveraging its installed base to drive recurring consumable sales of the Company’s cartridges, while continuing to grow its footprint ahead of planned U.S. market expansion (beyond Forensic Use Only settings) in the second half of 2025.

About Intelligent Bio Solutions Inc. 

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.

For more information, visit https://ibs.inc/

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent Bio Solutions’ public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Company Contact
Intelligent Bio Solutions Inc. 
info@ibs.inc  
LinkedIn | Twitter 

Investor & Media Contact
Valter Pinto, Managing Director 
KCSA Strategic Communications 
PH: (212) 896-1254 
INBS@kcsa.com

FAQ

What were Intelligent Bio Solutions (INBS) cartridge sales in July 2025?

INBS shipped 519 boxes containing over 12,500 cartridges in July 2025, marking a 60% increase compared to the previous year.

How does INBS's razor/razor blade business model work?

INBS uses a business model where they sell drug testing systems (razor) and generate recurring revenue through high-margin cartridge sales (razor blade) as consumables for their fingerprint sweat-based testing system.

When will INBS expand beyond Forensic Use Only settings in the U.S. market?

INBS plans to expand beyond Forensic Use Only settings in the U.S. market during the second half of 2025.

What new contracts has INBS secured recently?

INBS recently secured a significant multi-site, high-volume contract in the transportation sector, contributing to increased demand for their testing solutions.

What is driving INBS's revenue growth?

INBS's revenue growth is driven by recurring sales of high-margin cartridges, expansion of their installed base, and securing new large contracts, particularly in the transportation sector.